Alcyomics: Reducing safety risk to humans through innovative solutions




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Alcyomics: Reducing safety risk to humans through innovative solutions
Released on: July 31, 2016. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Alcyomics aim is to provide novel solutions for pre-clinical drug safety and efficacy testing for therapeutics including cellular therapies.
  • Summary
  • Transcript
  • Participants
  • Company
Alcyomics aim is to provide novel solutions for pre-clinical drug safety and efficacy testing for therapeutics including cellular therapies. Anne Dickinson, the founder of Alcyomics explains to Adrian Dawkes how using human in vitro skin explant assays they provide services to national and international customers in the Pharma, Cosmetic and Chemical industries enabling more cost effective commercialisation of products and or drugs.
Alcyomics aim is to provide novel solutions for pre-clinical drug safety and efficacy testing for therapeutics including cellular therapies. Anne Dickinson, the founder of Alcyomics explains to Adrian Dawkes how using human in vitro skin explant assays they provide services to national and international customers in the Pharma, Cosmetic and Chemical industries enabling more cost effective commercialisation of products and or drugs.
Anne is a Professor of Transplant Biology, Newcastle University. Anne also acts as Chair Of The Board.
Alcyomics is a UK based unique pre-clinical service provider using Skimuneā„¢, non-artificial human skin explants for safety and efficacy assessment of novel compounds and drugs.